Skip to main content

Table 2 Micafungin for the treatment of IC in daily clinical practice

From: Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study

Type of IC

Patients n (%)

 

< 18 years

≥ 18 years

Total

36 (33)

72 (67)

108 (100)

Proven IC*, n

13

45

58

Candidemia

13

41

54

Endocarditis

-

3

3

Intra-abdominal infections

-

1

1

Suspected IC, n

23

27

50

Diagnostic-driven therapy†

5

4

9

Empirical therapy

18

23

41

  1. IC, invasive candidiasis.
  2. Intra-abdominal infection was defined as Candida spp. isolation from peritoneal fluid with clinical signs of invasive infection, according to investigator’s clinical judgment.
  3. *Proven IC.
  4. Neonates (n = 7): C. parapsilosis (n = 4), C. albicans (n = 2), C. famata (n = 1).
  5. Children (n = 6): C. albicans (n = 4), C. parapsilosis (n = 1), C. glabrata (n = 1).
  6. Adults (n = 45): C. albicans (n = 28), C. parapsilosis (n = 3), C. glabrata (n = 6), C. tropicalis (n = 2), C. albicans + C. glabrata (n = 1), C. guilliermondii (n = 1), C. krusei (n = 1), C.krusei + C. lusitanie (n = 1), C. sake (n = 1), C. kefir (n = 1).
  7. †According to mannan antigen and/or (1,3)-β-D-Glucan, which resulted positive in 1/2 and 9/13 tested patients, respectively.